NASDAQ:THTX Theratechnologies Q2 2025 Earnings Report $3.16 +0.02 (+0.48%) As of 11:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Theratechnologies EPS ResultsActual EPS-$0.09Consensus EPS -$0.01Beat/MissMissed by -$0.08One Year Ago EPSN/ATheratechnologies Revenue ResultsActual Revenue$17,729.00 billionExpected Revenue$24.30 millionBeat/MissBeat by +$17,728.98 billionYoY Revenue GrowthN/ATheratechnologies Announcement DetailsQuarterQ2 2025Date7/9/2025TimeBefore Market OpensConference Call DateWednesday, July 9, 2025Conference Call Time8:30AM ETConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Theratechnologies Earnings HeadlinesTheratechnologies Reports Financial Results for the Second Quarter 2025July 9 at 7:30 AM | globenewswire.comTheratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?July 7 at 1:19 PM | seekingalpha.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 10 at 2:00 AM | Brownstone Research (Ad)Theratechnologies (NASDAQ:THTX) Stock Rating Lowered by Jones TradingJuly 5, 2025 | americanbankingnews.comTheratechnologies Stock (NASDAQ:THTX), Insider Trading ActivityJuly 3, 2025 | benzinga.comTheratechnologies Inc. (THTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comSee More Theratechnologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theratechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theratechnologies and other key companies, straight to your email. Email Address About TheratechnologiesTheratechnologies (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for people with metabolic and endocrine disorders. Founded in 1996 and headquartered in Montreal, Canada, the company operates under the ticker NASDAQ:THTX and TSX:TH and has established itself through targeted research in hormone regulation and metabolic control. The company’s lead product, EGRIFTA (tesamorelin for injection), is an FDA-approved growth hormone-releasing factor analog indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In addition to its marketed therapy, Theratechnologies maintains a diversified pipeline with clinical programs such as Tesomet, an investigational drug for hypothalamic obesity and rare metabolic disorders, and ongoing research into novel small molecules aimed at improving lipid and glucose metabolism. Theratechnologies manages a hybrid operating model combining in-house expertise in clinical development, regulatory affairs and commercial operations with strategic partnerships to expand its reach. The company markets EGRIFTA in the United States and Canada, while collaborating with regional partners in Europe and Latin America to obtain regulatory approvals and facilitate patient access. Manufacturing and distribution agreements ensure consistent supply through specialty pharmacies and hospital networks. Governed by an experienced leadership team, Theratechnologies is led by President and CEO Michel Ménard, who brings over two decades of pharmaceutical and biotechnology experience. The executive team and board of directors include industry veterans with backgrounds in endocrinology, regulatory strategy and global commercialization, underscoring the company’s commitment to advancing care for patients with complex metabolic needs.Written by Jeffrey Neal JohnsonView Theratechnologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Fastenal (7/14/2025)Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.